PRKDC

Across TCGA pan-cancer cohorts, PRKDC mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRKDC data layer compared with 28 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRKDC mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRKDC expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where PRKDC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.295	0.663	<.001	51	view →
HNSC	OS	Median	III,IV	0.760	0.943	.003	38	view →
LSCC	DFS	Tertile	II,III,IV	0.892	0.398	<.001	33	view →
CCRCC	OS	Median	IV	0.123	0.785	.009	31	view →
LUAD	DFS	Quartile	III,IV	0.894	0.421	.008	7	view →
COAD	DFS	Tertile	All	1.000	0.925	.046	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRKDC–PDAC (DFS)

Open the PDAC breakdown →